About

AgeisBio is a longevity biotech company dedicated to developing novel therapeutics aimed at expanding human healthspan.  As the global population ages, age-related conditions have become the leading cause of disability and create an unsustainable economic burden.  The company has made a significant breakthrough by discovering a biological target that can induce cellular rejuvenation in conditions of aging and degenerative disease, providing a concrete path toward creating next-generation medicines that prevent age-related decline and promote lasting health. 

The Unsustainable Burden of a Shortened Human Healthspan

AgeisBio’s core mission is to develop therapeutics that prevent the conditions responsible for declining human healthspan—the years lived in good health and quality of life. The primary cost of a shortened healthspan means people spend more years living with chronic disease, disability, and frailty.  By targeting the fundamental biological process of aging, interventions can delay or prevent the onset of multiple chronic diseases simultaneously.  People remain physically and cognitively functional for longer, allowing for extended engagement in work, social life, hobbies, and community contributions.  Focusing on delayed aging and healthspan extension is estimated to yield massive economic returns, often valued in the trillions of dollars over several decades.

AgeisBio's Approach 

AgeisBio's aging research is rooted in systems biology.  Research aims that focus on isolated elements or components of biology are not effective in longevity medicine since they lead to therapeutic interventions that act only on a single pathway to serve a single function.  At AgeisBio, we conducted our research to study how the components of biology interact together to develop a holistic view, by addressing mechanism at a functional level. This holistic view, which incorporates cellular-wide mechanisms, provides the scope necessary to address biological aging.  Using this systems biology approach, AgeisBio discovered a biological mechanism to induce gene expression in phenotypes of aging and degenerative diseases, leading to a therapy for cellular rejuvenation.  We're developing small molecules to modulate the mechanism and are currently in the hit-to-lead phase.

Our Vision & Future Directions

We're first taking our rejuvenation therapies to ophthalmology to address multiple indications in retinal degenerative diseases.  We plan to demonstrate our therapy's regenerative, neuroprotective, and reparative properties, as a proof of concept for use of our drug candidates in regenerative medicine.  We are also planning to demonstrate efficacy in preclinical models of dry-eyed AMD, diabetic retinopathy and glaucoma. 

We are committed to making a significant impact on those suffering from age-related conditions, like retinal degenerative diseases, and reducing the economic and societal burden of these diseases.  Join us on our journey to develop innovative therapies that promote longevity!